Abstract
The metal-based drugs have gained increasing attention in the fight against cancer. Ga(III) in the form of inorganic salts has demonstrated efficacy in the treatment of a number of malignancies in experimental animals and humans, and has therefore attracted considerable pharmaceutical interest. However, the poor hydrolytic stability of Ga(III) in physiological medium owing to its property of hard Lewis acid prevents its widespread use in systemic cancer chemotherapy. Complexation of suitable chelators capable of stabilising Ga(III) against hydrolysis affords an opportunity for overcoming this drawback. Thiosemicarbazone (TSC) derivatives, a class of well-studied iron chelators featuring softer donor sulfur, also were evaluated to possess antineoplastic activities in an arrary of tumour cell lines. The structural modifications can affect the activities of TSCs, and related structure-activity relationships (SAR) have been studied over these years. Combination of Ga(III) and TSCs that are both pharmaceutically active has proved to exert synergistic effects of each component in one compound in most cases, and may produce more potent Ga(III) drugs. In this review, the SAR of α(N)-heterocyclic thiosemicarbazone (HCT) analogues, a family of TSCs, were scrupulously surveyed, and the effect of Ga(III) complexation on their anticancer activity sparsely reported in literature was comparatively examined, in order to stimulate further advances in the field of gallium-based anticancer drugs.
Keywords: Gallium, anticancer activity, sulfur-containing chelator, thiosemicarbazone, structure-activity relationships, complexation effect.
Anti-Cancer Agents in Medicinal Chemistry
Title:α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Volume: 16 Issue: 8
Author(s): Shuhong Cao, Xiahui Chen, Ligen Chen and Jingwen Chen
Affiliation:
Keywords: Gallium, anticancer activity, sulfur-containing chelator, thiosemicarbazone, structure-activity relationships, complexation effect.
Abstract: The metal-based drugs have gained increasing attention in the fight against cancer. Ga(III) in the form of inorganic salts has demonstrated efficacy in the treatment of a number of malignancies in experimental animals and humans, and has therefore attracted considerable pharmaceutical interest. However, the poor hydrolytic stability of Ga(III) in physiological medium owing to its property of hard Lewis acid prevents its widespread use in systemic cancer chemotherapy. Complexation of suitable chelators capable of stabilising Ga(III) against hydrolysis affords an opportunity for overcoming this drawback. Thiosemicarbazone (TSC) derivatives, a class of well-studied iron chelators featuring softer donor sulfur, also were evaluated to possess antineoplastic activities in an arrary of tumour cell lines. The structural modifications can affect the activities of TSCs, and related structure-activity relationships (SAR) have been studied over these years. Combination of Ga(III) and TSCs that are both pharmaceutically active has proved to exert synergistic effects of each component in one compound in most cases, and may produce more potent Ga(III) drugs. In this review, the SAR of α(N)-heterocyclic thiosemicarbazone (HCT) analogues, a family of TSCs, were scrupulously surveyed, and the effect of Ga(III) complexation on their anticancer activity sparsely reported in literature was comparatively examined, in order to stimulate further advances in the field of gallium-based anticancer drugs.
Export Options
About this article
Cite this article as:
Cao Shuhong, Chen Xiahui, Chen Ligen and Chen Jingwen, α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (8) . https://dx.doi.org/10.2174/1871520616666160310142012
DOI https://dx.doi.org/10.2174/1871520616666160310142012 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Overview of Ribonucleotide Reductase Inhibitors: An Appealing Target in Anti-Tumour Therapy
Current Medicinal Chemistry Alternative Splicing and Tumor Progression
Current Genomics RNA Interference-Based Gene Silencing in Mice: The Development of a Novel Therapeutical Strategy
Current Pharmaceutical Design The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Applications of Gene Therapy to the Treatment of Chronic Pain
Current Gene Therapy New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential
Current Bioactive Compounds A Hybrid Discrete Imperialist Competition Algorithm for Gene Selection for Microarray Data
Current Proteomics Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry Tackling Chronic Pain and Inflammation through the Purinergic System
Current Medicinal Chemistry Targeting Notch Pathway in Cancer Diagnostics and Therapeutics: An Emerging Approach
Recent Patents on Anti-Cancer Drug Discovery Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses
Current Gene Therapy Effects of Dietary Broccoli on Human in Vivo Caffeine Metabolism: A Pilot Study on a Group of Jordanian Volunteers
Current Drug Metabolism Current Antioxidant Molecular Therapies for Oxidative Stress-Related Ailments
Current Gene Therapy Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Gynaecological Cancer Diagnostics: 99mTc-Cisplatin Complex as a Future Approach for Early, Prompt and Efficient Diagnosis of Gynaecological Cancer
Current Medical Imaging Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?
Current Cancer Drug Targets Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Caveolae and Caveolin-1: Novel Potential Targets for the Treatment of Cardiovascular Disease
Current Pharmaceutical Design Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets